drugset / Trial / NCT04536688
A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
Primary Objective • To assess the dose response relationship between RGLS4326 and ADPKD biomarkers Secondary Objectives * To characterize the pharmacokinetic (PK) properties of RGLS4326 in plasma and urine * To assess the safety and tolerability of RGLS4326
Timeline
- Start
- 2020-10-13
- Primary completion
- 2021-11-12
- Completion
- 2021-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RGLS4326 | Unknown | 0.1 mg/kg | Subcutaneous |
| Subject | RGLS4326 | Unknown | 0.3 mg/kg | Subcutaneous |
| Subject | RGLS4326 | Unknown | 0.5 mg/kg | Subcutaneous |
| Subject | RGLS4326 | Unknown | 1 mg/kg | Subcutaneous |